Literature DB >> 35018864

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Tomas Koltai1, Larry Fliegel2.   

Abstract

The flavonoid silymarin extracted from the seeds of Sylibum marianum is a mixture of 6 flavolignan isomers. The 3 more important isomers are silybin (or silibinin), silydianin, and silychristin. Silybin is functionally the most active of these compounds. This group of flavonoids has been extensively studied and they have been used as hepato-protective substances for the mushroom Amanita phalloides intoxication and mainly chronic liver diseases such as alcoholic cirrhosis and nonalcoholic fatty liver. Hepatitis C progression is not, or slightly, modified by silymarin. Recently, it has also been proposed for SARS COVID-19 infection therapy. The biochemical and molecular mechanisms of action of these substances in cancer are subjects of ongoing research. Paradoxically, many of its identified actions such as antioxidant, promoter of ribosomal synthesis, and mitochondrial membrane stabilization, may seem protumoral at first sight, however, silymarin compounds have clear anticancer effects. Some of them are: decreasing migration through multiple targeting, decreasing hypoxia inducible factor-1α expression, inducing apoptosis in some malignant cells, and inhibiting promitotic signaling among others. Interestingly, the antitumoral activity of silymarin compounds is limited to malignant cells while the nonmalignant cells seem not to be affected. Furthermore, there is a long history of silymarin use in human diseases without toxicity after prolonged administration. The ample distribution and easy accessibility to milk thistle-the source of silymarin compounds, its over the counter availability, the fact that it is a weed, some controversial issues regarding bioavailability, and being a nutraceutical rather than a drug, has somehow led medical professionals to view its anticancer effects with skepticism. This is a fundamental reason why it never achieved bedside status in cancer treatment. However, in spite of all the antitumoral effects, silymarin actually has dual effects and in some cases such as pancreatic cancer it can promote stemness. This review deals with recent investigations to elucidate the molecular actions of this flavonoid in cancer, and to consider the possibility of repurposing it. Particular attention is dedicated to silymarin's dual role in cancer and to some controversies of its real effectiveness.

Entities:  

Keywords:  antioxidant; cancer; invasion; migration; milk thistle; silybin; silymarin

Mesh:

Substances:

Year:  2022        PMID: 35018864      PMCID: PMC8814827          DOI: 10.1177/2515690X211068826

Source DB:  PubMed          Journal:  J Evid Based Integr Med        ISSN: 2515-690X


  393 in total

Review 1.  Modulation of WNT/β-catenin pathway in melanoma by biologically active components derived from plants.

Authors:  Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  Fitoterapia       Date:  2016-02-02       Impact factor: 2.882

2.  Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.

Authors:  S Beckmann-Knopp; S Rietbrock; R Weyhenmeyer; R H Böcker; K T Beckurts; W Lang; M Hunz; U Fuhr
Journal:  Pharmacol Toxicol       Date:  2000-06

3.  Inhibition of rat liver cytosolic glutathione S-transferase by silybin.

Authors:  A R Bartholomaeus; R Bolton; J T Ahokas
Journal:  Xenobiotica       Date:  1994-01       Impact factor: 1.908

4.  Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC.

Authors:  Anabela P. Rolo; Paulo J. Oliveira; António J.M. Moreno; Carlos M. Palmeira
Journal:  Hepatol Res       Date:  2003-07       Impact factor: 4.288

5.  Evaluation of the effect of Silybum marianum extract on menopausal symptoms: A randomized, double-blind placebo-controlled trial.

Authors:  Zohreh Saberi; Narjes Gorji; Zahra Memariani; Reihaneh Moeini; Hoda Shirafkan; Mania Amiri
Journal:  Phytother Res       Date:  2020-08-06       Impact factor: 5.878

6.  Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells.

Authors:  Lin-Hao Li; Li-Jun Wu; Yuan-Yuan Jiang; Shin-Ichi Tashiro; Satoshi Onodera; Fumiaki Uchiumi; Takashi Ikejima
Journal:  J Asian Nat Prod Res       Date:  2007 Sep-Dec       Impact factor: 1.569

7.  Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Authors:  Michael W Fried; Victor J Navarro; Nezam Afdhal; Steven H Belle; Abdus S Wahed; Roy L Hawke; Edward Doo; Catherine M Meyers; K Rajender Reddy
Journal:  JAMA       Date:  2012-07-18       Impact factor: 56.272

Review 8.  Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy.

Authors:  Maria Cristina Comelli; Ulrich Mengs; Carl Schneider; Marco Prosdocimi
Journal:  Integr Cancer Ther       Date:  2007-06       Impact factor: 3.279

9.  Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial.

Authors:  Ghazal Sadat Askarpour Moezian; Seyed Alireza Javadinia; Soodabeh Shahid Sales; Azar Fanipakdel; Sepideh Elyasi; Gholamreza Karimi
Journal:  J Oncol Pharm Pract       Date:  2021-04-16       Impact factor: 1.809

10.  Silibinin Inhibits Platelet-Derived Growth Factor-Driven Cell Proliferation via Downregulation of N-Glycosylation in Human Tenon's Fibroblasts in a Proteasome-Dependent Manner.

Authors:  Yi-Hao Chen; Ching-Long Chen; Da-Wen Lu; Chang-Min Liang; Ming-Cheng Tai; Jiann-Torng Chen
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

View more
  1 in total

Review 1.  Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Authors:  Tomas Koltai; Stephan Joel Reshkin; Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Khalid Omer Alfarouk; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.